IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

The post IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024 appeared first on InvestorPlace.

More From InvestorPlace

• The #1 AI Investment Might Be This Company You’ve Never Heard Of
• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• It doesn’t matter if you have $500 or $5 million. Do this now.